G B Vogelsang

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi request reprint How I treat chronic graft-versus-host disease
    G B Vogelsang
    Oncology Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231 1000, USA
    Blood 97:1196-201. 2001
  2. pmc Acute graft versus host disease
    David A Jacobsohn
    Robert H Lurie Comprehensive Cancer Center and Division of Hematology Oncology Transplant, Children s Memorial Hospital, Chicago, IL, USA
    Orphanet J Rare Dis 2:35. 2007
  3. ncbi request reprint Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant
    Georgia B Vogelsang
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting Blaustein Cancer Research Building, 1650 Orleans Street, Baltimore, Maryland 21231, USA
    Annu Rev Med 54:29-52. 2003
  4. ncbi request reprint Allogeneic bone marrow transplantation in patients with sensitive low-grade lymphoma or mantle cell lymphoma
    J G Berdeja
    Department of Oncology, Johns Hopkins University, Baltimore, Maryland, USA
    Biol Blood Marrow Transplant 7:561-7. 2001
  5. ncbi request reprint Development of a prognostic model for grading chronic graft-versus-host disease
    G Akpek
    Johns Hopkins Oncology Center, Division of Hematologic Malignancies BMT, and Oncology Biostatistics, Baltimore, MD 21231, USA
    Blood 97:1219-26. 2001
  6. ncbi request reprint Clinical importance of confirming or excluding the diagnosis of chronic graft-versus-host disease
    D A Jacobsohn
    Department of Oncology and Pediatrics, Hematologic Malignancies, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Bone Marrow Transplant 28:1047-51. 2001
  7. ncbi request reprint Pancreatic insufficiency in patients with chronic graft-versus-host disease
    G Akpek
    Hematologic Malignancies, Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Bone Marrow Transplant 27:163-6. 2001
  8. ncbi request reprint Long-term results of blood and marrow transplantation for Hodgkin's lymphoma
    G Akpek
    Johns Hopkins Oncology Center, Baltimore, MD 21231, USA
    J Clin Oncol 19:4314-21. 2001
  9. ncbi request reprint Acute bleeding complications in patients after bone marrow transplantation
    S Nevo
    Department of Oncology, The Bunting Blaustein Building for Cancer Research, Baltimore, Maryland 21231 1000, USA
    Curr Opin Hematol 8:319-25. 2001
  10. ncbi request reprint Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: preliminary findings
    G B Vogelsang
    Department of Oncology, Johns Hopkins Oncology Center, Baltimore, MD 21287-8943, USA
    Bone Marrow Transplant 27:1255-62. 2001

Collaborators

Detail Information

Publications57

  1. ncbi request reprint How I treat chronic graft-versus-host disease
    G B Vogelsang
    Oncology Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231 1000, USA
    Blood 97:1196-201. 2001
    ..It reviews the pathophysiology, risk factors, clinical manifestations, evaluation, treatment, and supportive care of chronic GVHD...
  2. pmc Acute graft versus host disease
    David A Jacobsohn
    Robert H Lurie Comprehensive Cancer Center and Division of Hematology Oncology Transplant, Children s Memorial Hospital, Chicago, IL, USA
    Orphanet J Rare Dis 2:35. 2007
    ..Additional management issues are attention to wound infections in skin GVHD and fluid/nutrition management in gastrointestinal GVHD. About 50% of patients with acute GVHD will eventually have manifestations of chronic GVHD...
  3. ncbi request reprint Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant
    Georgia B Vogelsang
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting Blaustein Cancer Research Building, 1650 Orleans Street, Baltimore, Maryland 21231, USA
    Annu Rev Med 54:29-52. 2003
    ..One persistent problem has been graft-versus-host disease (GVHD). This article reviews the basic biology of GVHD, clinical manifestations of acute and chronic GVHD, prophylaxis and treatment of acute GVHD, and treatment of chronic GVHD...
  4. ncbi request reprint Allogeneic bone marrow transplantation in patients with sensitive low-grade lymphoma or mantle cell lymphoma
    J G Berdeja
    Department of Oncology, Johns Hopkins University, Baltimore, Maryland, USA
    Biol Blood Marrow Transplant 7:561-7. 2001
    ..Thus, if there is a role for allogeneic BMT in the management of patients with these tumors, it is early in the course of the disease...
  5. ncbi request reprint Development of a prognostic model for grading chronic graft-versus-host disease
    G Akpek
    Johns Hopkins Oncology Center, Division of Hematologic Malignancies BMT, and Oncology Biostatistics, Baltimore, MD 21231, USA
    Blood 97:1219-26. 2001
    ..5, and more than 3.5 were 91%, 71%, 22%, and 4% (P =.2,.005, and <.001), respectively. It was concluded that these prognostic models might be useful in grouping the patients with similar outcome...
  6. ncbi request reprint Clinical importance of confirming or excluding the diagnosis of chronic graft-versus-host disease
    D A Jacobsohn
    Department of Oncology and Pediatrics, Hematologic Malignancies, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Bone Marrow Transplant 28:1047-51. 2001
    ..We conclude that since the therapy for this disease has significant toxicities and since what appears to represent cGVHD may actually be another disease, correct diagnosis of cGVHD or exclusion of this diagnosis is essential...
  7. ncbi request reprint Pancreatic insufficiency in patients with chronic graft-versus-host disease
    G Akpek
    Hematologic Malignancies, Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Bone Marrow Transplant 27:163-6. 2001
    ..The pathogenesis of pancreatic insufficiency in these patients is unknown. Pancreatic enzyme supplements can be very effective in treating this rare condition...
  8. ncbi request reprint Long-term results of blood and marrow transplantation for Hodgkin's lymphoma
    G Akpek
    Johns Hopkins Oncology Center, Baltimore, MD 21231, USA
    J Clin Oncol 19:4314-21. 2001
    ..CONCLUSION: There seems to be a clinical graft-versus-HL effect associated with allo BMT. Allo BMT for HL also seems to have a lower risk of secondary AML/MDS than auto BMT. Thus, allo BMT warrants continued study in HL...
  9. ncbi request reprint Acute bleeding complications in patients after bone marrow transplantation
    S Nevo
    Department of Oncology, The Bunting Blaustein Building for Cancer Research, Baltimore, Maryland 21231 1000, USA
    Curr Opin Hematol 8:319-25. 2001
    ..Given that a trigger of 10 x 10(9)/L has become accepted for prophylactic platelet transfusions, care should be taken to ensure that parameters other than the incidence of bleeding have not been adversely affected...
  10. ncbi request reprint Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: preliminary findings
    G B Vogelsang
    Department of Oncology, Johns Hopkins Oncology Center, Baltimore, MD 21287-8943, USA
    Bone Marrow Transplant 27:1255-62. 2001
    ..Larger clinical trials are warranted to determine the optimum dose and route of MMF administration for GVHD, as well as the comparative safety and efficacy of MMF-containing regimens...
  11. ncbi request reprint High incidence of graft failure in children receiving CD34+ augmented elutriated allografts for nonmalignant diseases
    C H McDonough
    Departments of Oncology and Pediatrics, Johns Hopkins University, Baltimore, MD 21287, USA
    Bone Marrow Transplant 31:1073-80. 2003
    ..Future efforts will seek to preserve the benefits of elutriation with CD34+ selection by increasing immune ablation of the preparative regimen and/or increasing posttransplant immune suppression...
  12. ncbi request reprint Outpatient-based bone marrow transplantation for hematologic malignancies: cost saving or cost shifting?
    J D Rizzo
    School of Medicine, School of Nursing, Oncology Center, and Program for Medical Technology and Practice Assessment, Johns Hopkins University, Baltimore, MD, USA
    J Clin Oncol 17:2811-8. 1999
    ..To determine whether a shift in care from an inpatient-based to an outpatient-based bone marrow transplantation (BMT) program decreased charges to payers without increasing clinical complications or out-of-pocket costs to patients...
  13. ncbi request reprint Acute bleeding and thrombocytopenia after bone marrow transplantation
    S Nevo
    Johns Hopkins Cancer Center, Baltimore, MD, USA
    Bone Marrow Transplant 27:65-72. 2001
    ..Thrombocytopenia may be an important clinical sign in NBLD patients, and should be further explored in relation to acute toxicities other than bleeding...
  14. ncbi request reprint A high-dose pulse steroid regimen for controlling active chronic graft-versus-host disease
    G Akpek
    Division of Hematologic Malignancies BMT, The Johns Hopkins Oncology Center, Baltimore 21231, USA
    Biol Blood Marrow Transplant 7:495-502. 2001
    ..Further studies are warranted to maintain the efficacy of this regimen by combining with new active agents in cGVHD...
  15. doi request reprint Skin response using NIH consensus criteria vs Hopkins scale in a phase II study for steroid-refractory chronic GVHD
    D A Jacobsohn
    Robert H Lurie Comprehensive Cancer Center of Northwestern University, Baltimore, MD, USA
    Bone Marrow Transplant 44:813-9. 2009
    ..Early assessment of skin softening may be important if trying to detect the activity of a particular agent in chronic GVHD. Further validation of the NIH scale is ongoing, which should produce a clinically useful and predictive scale...
  16. ncbi request reprint Using point-of-care CD34 enumeration to optimize PBSC collection conditions
    S J Noga
    The Johns Hopkins Hematopoietic and Therapeutic Support Service, Baltimore, MD 21205, USA
    Cytotherapy 3:11-8. 2001
    ..Although not a replacement for conventional flow cytometry, it meets the requirements for a point-of-care procedure...
  17. ncbi request reprint Risk factors for post-stem cell transplant sinusitis
    A M Thompson
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Bone Marrow Transplant 29:257-61. 2002
    ..Patients with GVHD were 4.3 times more likely than patients without GVHD to develop sinusitis post transplant (95% CI: 1.7-11.0, P = 0.002). Acute GVHD places patients at greater risk of developing sinus infections...
  18. ncbi request reprint Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide
    P V O'Donnell
    Bone Marrow Transplantation Program, The Sidney Kimmel Cancer Center, Johns Hopkins, Baltimore, Maryland, USA
    Biol Blood Marrow Transplant 8:377-86. 2002
    ..Clinically significant antitumor responses occur, even among patients who reject their donor grafts...
  19. ncbi request reprint Von Willebrand factor-cleaving protease activity and proteolysis of von Willebrand factor in bone marrow transplant-associated thrombotic microangiopathy
    S Arai
    Johns Hopkins Oncology Center, Johns Hopkins Hospital, Baltimore, Maryland 21231 1000, USA
    Hematol J 2:292-9. 2001
    ..In this study, we investigated the role of the vWF protease and vWF proteolysis in the pathogenesis of BMT-associated TM of the fulminant type...
  20. ncbi request reprint Weight loss and malnutrition in patients with chronic graft-versus-host disease
    D A Jacobsohn
    Oncology and Pediatrics, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Bone Marrow Transplant 29:231-6. 2002
    ..We also conclude that treating cGVHD aggressively may help reverse weight loss and malnutrition, which may be independent risk factors for mortality in this population...
  21. ncbi request reprint Lymphocytic pneumonitis as the manifestation of acute graft-versus-host disease of the lung
    Javier Bolaños-Meade
    Blood and Marrow Transplant Program, University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, USA
    Am J Hematol 79:132-5. 2005
    ..Its diagnosis requires work-up to rule out an infectious etiology and a biopsy to confirm histology...
  22. ncbi request reprint Pentostatin in steroid-refractory acute graft-versus-host disease
    Javier Bolaños-Meade
    Division of Hematologic Malignancies, Department of Oncology, Johns Hopkins Univeristy, Baltimore, MD 21231, USA
    J Clin Oncol 23:2661-8. 2005
    ..In steroid-refractory aGVHD, mortality is very high. Pentostatin, a potent inhibitor of adenosine deaminase, induces lymphocyte apoptosis and may be useful in the treatment of this condition...
  23. ncbi request reprint Gastrointestinal toxicity from the preparative regimen is associated with an increased risk of graft-versus-host disease
    Jenna Goldberg
    Sidney Kimmel Comprehensive Cancer Center at John Hopkins, Baltimore, MD, USA
    Biol Blood Marrow Transplant 11:101-7. 2005
    ..Prospective trials would have to test whether acute GVHD prophylaxis could be adjusted according to this risk. This may result in a greater graft-versus-tumor effect for patients with less risk of acute GVHD...
  24. ncbi request reprint Novel strategies for steroid-refractory acute graft-versus-host disease
    Javier Bolaños-Meade
    Department of Medicine, University of Maryland Greenebaum Cancer Center and University of Maryland School of Medicine, Baltimore, Maryland, USA
    Curr Opin Hematol 12:40-4. 2005
    ..Patients developing graft-versus-host disease who fail to respond to steroids have a poor prognosis. In this group of people, morbidity and mortality are very high...
  25. ncbi request reprint The effects of interleukin 10 and interferon gamma cytokine gene polymorphisms on survival after autologous bone marrow transplantation for patients with breast cancer
    Julie M Wu
    The School of Medicine and the Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University, Baltimore, Maryland 21231, USA
    Biol Blood Marrow Transplant 11:455-64. 2005
    ..Additional studies are necessary to further define the influence of IL-10 and IFN-gamma on the immune response after BMT...
  26. ncbi request reprint Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report
    Howard M Shulman
    Department of Pathology, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, University of Washington School of Medicine, Seattle, Washington 98109, USA
    Biol Blood Marrow Transplant 12:31-47. 2006
    ..Consensus recommendations and suggested data-capture forms should be validated in prospective clinicopathologic studies...
  27. ncbi request reprint Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions
    Carol Ann Huff
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, Baltimore, MD 21231, USA
    Biol Blood Marrow Transplant 12:414-21. 2006
    ..However, with the exception of CML, most patients die of their underlying disease because of insufficient antitumor activity even with active GVHD...
  28. ncbi request reprint National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report
    Paul J Martin
    Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, Washington 98109 1024, USA, and Hopital St Louis, Paris, France
    Biol Blood Marrow Transplant 12:491-505. 2006
    ..The use of consistent standards in clinical trial designs to evaluate agents that have activity in pathogenic pathways could facilitate advances in the treatment of chronic GVHD...
  29. ncbi request reprint Grover's Disease after Bone Marrow Transplantation
    Javier Bolaños-Meade
    Biol Blood Marrow Transplant 13:1116-7. 2007
  30. pmc Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma
    Javier Bolaños-Meade
    George W Santos Bone Marrow Transplant Service, Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Biol Blood Marrow Transplant 13:1185-91. 2007
    ..The administration of oral cyclosporine followed by interleukin-2 and gamma-interferon is generally not well tolerated, and does not appear to be an effective method to induce autologous GVHD in patients receiving autologous PBSC grafts...
  31. ncbi request reprint Chronic graft-versus-host disease
    Javier Bolaños-Meade
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Curr Pharm Des 14:1974-86. 2008
    ..Novel agents such as pentostatin, mycophenolate mofetil, rituximab, extracorporeal photochemotherapy, etc. are improving the outcome of steroid refractory chronic graft-versus-host disease...
  32. ncbi request reprint Pentostatin - pharmacology, immunology, and clinical effects in graft-versus-host disease
    Meghan Higman
    Johns Hopkins University School of Medicine, Department of Oncology, 2M89 Bunting Blaustein Building, 1650 Orleans Street, Baltimore, MD 21231, USA
    Expert Opin Pharmacother 5:2605-13. 2004
    ..Although many of these studies are ongoing, this agent has promise as a novel immunosuppressive agent with a new mechanism of action...
  33. ncbi request reprint Association of Foxp3 regulatory gene expression with graft-versus-host disease
    Yuji Miura
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Blood 104:2187-93. 2004
    ..The decrease in regulatory mechanisms after transplantation appears to provide an environment permissive to the development of GVHD...
  34. ncbi request reprint Chronic graft versus host disease
    Meghan A Higman
    The Sidney Kimmel Comprehensive Cancer at Johns Hopkins, Baltimore, MD, USA
    Br J Haematol 125:435-54. 2004
    ..We describe the risk factors for developing chronic GvHD, its presentation and the current treatment options for both initial therapy and secondary treatment...
  35. ncbi request reprint Novel pharmacotherapeutic approaches to prevention and treatment of GVHD
    David A Jacobsohn
    Oncology and Pediatrics, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Drugs 62:879-89. 2002
    ..The numerous new treatment modalities presented should improve the outlook for patients with acute and chronic GVHD...
  36. ncbi request reprint Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment
    Sally Arai
    Johns Hopkins Oncology Center, Baltimore, Maryland, USA
    Biol Blood Marrow Transplant 8:155-60. 2002
    ..Patients with steroid-refractory GVHD should be enrolled in clinical study until there are data to support a standard salvage therapy...
  37. ncbi request reprint Autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide purging for acute myeloid leukaemia beyond first remission: a 10-year experience
    B Douglas Smith
    Johns Hopkins Oncology Center, Bunting Blaustein Cancer Research Building, Rm 246, 1650 Orleans Street, Baltimore, MD 21231, USA
    Br J Haematol 117:907-13. 2002
    ..4HC-purged autologous BMT produced results similar to allogeneic BMT for AML patients beyond first remission...
  38. ncbi request reprint Hepatitic variant of graft-versus-host disease after donor lymphocyte infusion
    Gorgun Akpek
    Department of Oncology, Pathology, and Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Blood 100:3903-7. 2002
    ..These observations suggest that GVHD that occurs after DLI may have distinct clinical features. Hepatitic-variant GVHD should be considered in the differential diagnosis in DLI recipients with unexplained hepatitis...
  39. ncbi request reprint Myxedema ascites in the posttransplant setting: case report
    Colleen H McDonough
    Department of Oncology, Johns Hopkins University, 600 North Wolfe Street, Baltimore, MD 21287, USA
    Am J Hematol 71:216-8. 2002
    ..This case illustrates the importance of considering a broad differential diagnosis in posttransplant patients, especially those in whom the clinical course is atypical...
  40. ncbi request reprint Gastrointestinal involvement in chronic graft-versus-host disease: a clinicopathologic study
    Gorgun Akpek
    Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Biol Blood Marrow Transplant 9:46-51. 2003
    ..An isolated form of chronic GI GVHD confirmed by histology is an uncommon phenomenon in the actual clinical setting...
  41. ncbi request reprint Pentostatin for the treatment of chronic graft-versus-host disease in children
    Jenna D Goldberg
    Division of Hematological Malignancies, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, U S A
    J Pediatr Hematol Oncol 25:584-8. 2003
    ..If these promising results continue, a trial of pentostatin as a first-line therapy for cGVHD should be considered to potentially reduce our dependence on high-dose steroids for its treatment...
  42. ncbi request reprint Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells
    Carol Ann Huff
    Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Baltimore, MD, USA
    Biol Blood Marrow Transplant 9:312-9. 2003
    ..Unlike chronic myelogenous leukemia, the antimyeloma effect of allogeneic T cells rarely occurs in the absence of clinically significant GVHD...
  43. ncbi request reprint Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study
    Gorgun Akpek
    Department of Oncology, Johns Hopkins University, Baltimore, MD, USA
    Blood 102:802-9. 2003
    ..Although the new clinical grading based on the model is promising because of its utility across multiple independent data sets, prospective validation is needed...
  44. ncbi request reprint Infliximab for steroid-refractory acute GVHD: a case series
    David A Jacobsohn
    Department of Pediatrics, The Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
    Am J Hematol 74:119-24. 2003
    ..Furthermore, we do not know the correct dose or schedule to use with this drug. Given these data, controlled studies assessing dose and timing of administration may be warranted to study infliximab in acute GVHD...
  45. ncbi request reprint Anti-cytokine therapy for the treatment of graft-versus-host disease
    David A Jacobsohn
    Department of Pediatrics, Northwestern University, The Feinberg School of Medicine, USA
    Curr Pharm Des 10:1195-205. 2004
    ..Developments of combination therapy for treatment of both acute and chronic GVHD will likely yield better results than monotherapy. The numerous new treatment modalities presented should improve the outlook for acute and chronic GVHD...
  46. pmc Chronic Graft-versus-Host Disease--implementation of the National Institutes of Health Consensus Criteria for Clinical Trials
    Linda M Griffith
    Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Biol Blood Marrow Transplant 14:379-84. 2008
  47. ncbi request reprint Phase II study of pentostatin in patients with corticosteroid-refractory chronic graft-versus-host disease
    David A Jacobsohn
    Robert H Lurie Comprehensive Cancer Center and Division of Hematology Oncology Transplant, Children s Memorial Hospital, Chicago, IL, USA
    J Clin Oncol 25:4255-61. 2007
    ..Pentostatin, a potent inhibitor of adenosine deaminase, has activity in acute GVHD. We examined the toxicity and efficacy of pentostatin in a prospective phase II trial in corticosteroid-refractory cGVHD...
  48. ncbi request reprint A systematic approach to hepatic complications in hematopoietic stem cell transplantation
    Sally Arai
    Johns Hopkins Oncology Center, Baltimore, MD 21231, USA
    J Hematother Stem Cell Res 11:215-29. 2002
    ..Updated treatment options are also discussed. It is hoped that a standard approach will help to streamline clinical management of these very complex patients...
  49. ncbi request reprint Profound thrombocytopenia and survival of hematopoietic stem cell transplant patients without clinically significant bleeding, using prophylactic platelet transfusion triggers of 10 x 10(9) or 20 x 10(9) per L
    Shoshan Nevo
    Johns Hopkins University, Baltimore, Maryland, USA
    Transfusion 47:1700-9. 2007
    ..This retrospective analysis evaluates thrombocytopenia and survival of 381 hematopoietic stem cell transplant (HSCT) patients without clinically significant bleeding, with 10 x 10(9) and 20 x 10(9) per L prophylactic triggers...
  50. ncbi request reprint Acute graft-versus-host disease
    Javier Bolaños-Meade
    University of Maryland Greenebaum Cancer Center, Baltimore, MD, USA
    Clin Adv Hematol Oncol 2:672-82. 2004
    ..Recent advances in the understanding of the induction and propagation of GVHD have lead to new transplant strategies and treatment of aGVHD. This overview covers the basic pathophysiology, prophylaxis and treatment of this disorder...
  51. ncbi request reprint Acute bleeding complications in patients after hematopoietic stem cell transplantation with prophylactic platelet transfusion triggers of 10 x 10(9) and 20 x 10(9) per L
    Shoshan Nevo
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Bunting Blaustein Cancer Research Building, Baltimore, Maryland, USA
    Transfusion 47:801-12. 2007
    ..This retrospective analysis evaluates utilization of blood transfusions, risk of bleeding, and survival in 480 HSCT patients at 10 x 10(9) and 20 x 10(9) per L prophylactic trigger levels...
  52. ncbi request reprint Montelukast in chronic graft-versus-host disease: a breath of fresh air?
    Javier Bolaños-Meade
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Transplantation 83:527-8. 2007
  53. ncbi request reprint Mesenchymal stem cells and organ transplantation: current status and promising future
    Javier Bolaños-Meade
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Transplantation 81:1388-9. 2006
  54. ncbi request reprint Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working
    Daniel Couriel
    University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Biol Blood Marrow Transplant 12:375-96. 2006
    ..Optimal care of patients with chronic GVHD often requires a multidisciplinary approach...
  55. ncbi request reprint Hepatic venoocclusive disease in blood and bone marrow transplantation in children: incidence, risk factors, and outcome
    Georgia B Vogelsang
    J Pediatr Hematol Oncol 24:706-9. 2002
  56. ncbi request reprint Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report
    Kirk R Schultz
    British Columbia Children s Hospital, University of British Columbia, Vancouver, British Columbia, Canada
    Biol Blood Marrow Transplant 12:126-37. 2006
    ..Both approaches have merit and should be pursued. The consistent treatment and standardized documentation needed to support biomarker studies are most likely to be satisfied in prospective clinical trials...
  57. ncbi request reprint Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report
    Steven Z Pavletic
    National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1203, USA
    Biol Blood Marrow Transplant 12:252-66. 2006
    ..The proposed response criteria are based on current expert consensus opinion and are intended to improve consistency in the conduct and reporting of chronic GVHD trials, but their use remains to be demonstrated in practice...